

Quality Improvement Committee (QIC) Meeting

11/25/2015

11:00am-12:00pm

Shasta Room, Health Dept.

Meeting called by: Lucero Robles, QI Manager

Facilitator: Lucero Robles

Attendees: Please refer to sign-in sheet for QI Committee Meeting

Minutes

Agenda item:	Policy 100: Division Policies and Procedures	Presenter:	Lucero Robles
Discussion:	Updated policy to reflect current practice for updating policies/procedures and informing staff of changes.		
Conclusion	Approved		
Agenda item:	Policy 336 Advisement of Rights to Involuntary Patients (5250)	Presenter:	Lucero Robles
Discussion:	<p>Explained intent of policy: Define a set of standard practices to be implemented for advisement to patients regarding involuntary detention for intensive treatment for mental health disorders.</p> <ul style="list-style-type: none"> The policy sets a standard for practice guidelines which inpatient mental health unit social worker will notify the patient of the advisement of rights to involuntary patients. The procedure included standard for advising the patient and documentation of such. 		
Conclusion	Approved		
Agenda item:	Policy 507: Prescription of Benzodiazepines	Presenter:	Lucero Robles
Discussion:	<p>Explained intent of policy: Define a set of standard practices to be implemented for the prescription practices for Benzodiazepines</p> <ul style="list-style-type: none"> The policy sets a standard for practice guidelines for the prescription of benzodiazepines in outpatient clinics. The policy includes a contract that is to be explained to client prior to prescribing of benzodiazepines. The policy clearly states Alprazolam (Xanax) is not prescribed in our clinics due to risks associated with taking this drug. 		
Conclusion	Approved		
Agenda item:	Policy 508: Prescribing of VIBVITROL	Presenter:	Lucero Robles

Discussion:	<p>Explained intent of policy: Define a set of standard practices to be implemented for the prescription and administration of VIVITROL; an injectable medication.</p> <ul style="list-style-type: none"> • The policy sets a standard for practice guidelines for the prescription VIVITROL, including information on contraindications, caution of use, informed consent, and administration instructions. • The policy requires the doctor to discuss informed consent, warning of opiate use, and provide the patient with an FDA regulations handout with additional information on VIVITROL 	
Conclusion	Approved	
✓No items tabled		
<i>Other Items</i>		
Next Meeting:	<i>January 28, 2016</i>	